(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 22 July 2004 (22.07.2004)

PCT

(10) International Publication Number WO 2004/060278 A3

(51) International Patent Classification⁷: C12P 19/34, C07H 21/02

C12Q 1/68,

(21) International Application Number:

PCT/US2003/038761

(22) International Filing Date:

5 December 2003 (05.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/431,319	6 December 2002 (06.12.2002)	US
10/326,051	18 December 2002 (18.12.2002)	US
10/325,527	18 December 2002 (18.12.2002)	US
10/325,526	18 December 2002 (18.12.2002)	US
10/323,233	18 December 2002 (18.12.2002)	US
60/443,443	29 January 2003 (29.01.2003)	US
60/443,788	30 January 2003 (30.01.2003)	US
60/447,529	14 February 2003 (14.02.2003)	US
60/501,926	11 September 2003 (11.09.2003)	US

(71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 1896 Rutherford Road, Carlsbad, CA 92008 (US).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ECKER, David, J. [US/US]; 1041 Saxony Road, Encinitas, CA 92024 (US). GRIFFEY, Richard, H. [US/US]; 360 Barsby Street, Vista, CA 92084 (US). SAMPATH, Rangarajan [IN/US]; 12223 Mannix Road, San Diego, CA 92129 (US). HOFSTADLER, Steven, A. [US/US]; 5014 Viewridge Way, Oceanside, CA 92056 (US). MCNEIL, John [US/US]; 6389 Castejon Drive, La Jolla, CA 92037 (US). CROOKE, Stanley, T. [US/US]; 3211 Piragua

Street, Carlsbad, CA 92009 (US). **BLYN, Lawrence, B.** [US/US]; 27892 Perales, Mission Viejo, CA 92692 (US). **RANKEN, Raymond** [US/US]; 231 Horizon Drive, Encinitas, CA 92024 (US). **HALL, Thomas, A.** [US/US]; 5239 Wohlford Street, Oceanside, CA 92056 (US).

- (74) Agent: LEGAARD, Paul, K.; Cozen O'Connor, 1900 Market Street, Philadelphia, PA 19103 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 2 March 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND ANIMALS

(57) Abstract: The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.





International application No.

PCT/US03/38761

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68; C12P 19/34; C07H 21/02 US CL : 435/6, 91.2; 536/23.1 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED					
	cumentation searched (classification system followed by	v classification symbols)			
	35/6, 91.2; 536/23.1	, 0.0.00			
Documentatio	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
	ta base consulted during the international search (name ontinuation Sheet	of data base and, where practicable, sear	ch terms used)		
	UMENTS CONSIDERED TO BE RELEVANT		D. 1. 1. N		
Category *	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.		
х	MUDDIMAN et al. Characterization of PCR productionization FTICR Mass spectrometry. Analytical Chemical	ts from Bacilli using electrospray	1-6, 27-39		
Y	pages 3705-3712, see entire document.	mistry. Of November 1990, Vol. 30,	7, 9-24		
Y	Y US 6,043,031 A (KOSTER et al) 28 March 2000 (28.03.2000), see entire document.		1-7, 9-24, 27-39		
Y BORROW et al. SiaD PCR Elisa for confirmation and identifit W135 meningococcal infections. FEMS Microbiological Lette 209-214 Y BOIVIN-JAHNS et al. Bacterial diversity in a deep subsurface and Environmental Microbiology. September 1996, Vol. 62, I page 3406, column 2, subheading "rDNA amplification".		d identification of serogroup Y and ical Letters. 1998, Vol. 159, pages	9-24		
		Vol. 62, No. 9, pages 3405-3412, see	1-7, 9-24, 27-39		
Y	HURST et al. MALDI-TOF analysis of polymerase methanotrophic bacteria. Analytical Chemistry. 01 July 2698, see entire document.	chain reaction products from uly 1998, Vol. 70, No.13, pages 2693-	1-7, 9-24, 27-39		
Further	documents are listed in the continuation of Box C.	See patent family annex.			
· '	pecial categories of cited documents:	"T" later document published after the inte date and not in conflict with the applic principle or theory underlying the inve	ation but cited to understand the		
	t defining the general state of the art which is not considered to be				
ł	plication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be conside when the document is taken alone	red to involve an inventive step		
"L" document establish specified)	t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the considered to involve an inventive ster combined with one or more other such	when the document is a document, such combination		
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	e art		
"P" document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed					
Date of the actual completion of the international search Date of mailing of the international search Date of mailing of the international search			ch report		
28 July 2003 (28.07.2003)		11/			
	ailing address of the ISA/US ail Stop PCT, Attn: ISA/US	[] [] [] [] [] [] [] [] [] []	'///KO		
Co	ommissioner of Patents	Jeffrey Fredman	/		
	. Box 1450 xandria, Virginia 22313-1450	Telephone No. 703-308-0196			
Facsimile No. (703) 305-3230					

Form PCT/ISA/210 (second sheet) (July 1998)

PCT/US03/38761	

C.	(Continuation)	DOCUMENTS	CONSIDERED TO	BE RELEVANT
----	----------------	-----------	---------------	-------------

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	WO 97/37041 A2 (SEQUENOM, INC.) 09 October 1997 (09.10.1997), see entire document.	1-7, 9-24, 27-39

INTERNATIONAL SEARCH REPORT	PCT/US03/38761

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-7, 9-24, 27-39, drawn to methods of screening for disease agents.

Group II, claim(s) 8, drawn to methods of screening for primer sets.

Group III, claim(s) 25-26, drawn to methods of pharmacogenetic analysis.

Group IV, claim(s) 40-49, drawn to primer pairs.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

Each primer pair of Group IV represents a different species. There are 185 different primer pairs listed in claim 40.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is no special technical feature over the prior art which links Groups I-IV. Claim 1 is anticipated by Muddiman et al (Anal. Chem. (1996) 68:3705-3712) who teaches a method of identifying a bioagent which is unknown comprising (a) contacting nucleic acid from the bioagent with a pair of primers which hybridize to sequences that flank a variable region (see page 3707, column 1, where the primers are drawn to the 16S and 235 rRNA sequences, which are variable at some level at those Iocations) (b) amplifying the variable nucleic acid sequence to produce an amplification product (see page 3707, column 1), (c) determining the molecular mass of the amplification product by a biomass detection method, here FTICR Mass spectrometry (see page 3707, column 2), (d) comparing the molecular mass to molecular masses of known bioagents thereby identifying the ''unknown'' bioagent (see figures 2,-5 where the masses of two different species are compared).

Since claim 1 is anticipated, there is no special technical feature over the art which links the claims, rendering the lack of unity requirement proper.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The species are not structurally related and are drawn from different sequences, including the 16S rRNA, 23s rRNA and RNAse P sequences. The primers share no common core structure. Therefore, the species are not related because they share no special technical feature in common.

Continuation of B. FIELDS SEARCHED Item 3:

EAST, MEDLINE, BIOSIS, CAPLUS search terms: MALDI, FTICR, mass, spectrometry, PCR, polymerase, chain, primer, oligo, DNA, nucleic, hybridize, bacteria, universal, diversity		

International application No.

PCT/US03/38761

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)		
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:		
2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)		
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet		
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.		
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite		
payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7,9-24 and 27-39		
Remark on Protest		
No protest accompanied the payment of additional search fees.		